Leerink Partnrs Raises Earnings Estimates for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Exact Sciences in a report released on Thursday, February 20th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $0.12 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.27 EPS, Q2 2026 earnings at $0.22 EPS, FY2026 earnings at $0.93 EPS and FY2027 earnings at $1.54 EPS.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%.

A number of other research firms have also weighed in on EXAS. TD Cowen increased their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Piper Sandler lowered their price target on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Bank of America lowered their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday. Sanford C. Bernstein increased their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Thursday. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.06.

Exact Sciences Stock Down 0.5 %

NASDAQ:EXAS opened at $49.26 on Friday. The firm has a market capitalization of $9.15 billion, a P/E ratio of -8.84 and a beta of 1.24. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62. The company’s fifty day moving average price is $54.91 and its 200-day moving average price is $60.01. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Hedge Funds Weigh In On Exact Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Thompson Investment Management Inc. lifted its holdings in Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after purchasing an additional 36,505 shares in the last quarter. WCM Investment Management LLC lifted its stake in shares of Exact Sciences by 1,153.2% in the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after buying an additional 172,821 shares in the last quarter. Simplify Asset Management Inc. lifted its stake in shares of Exact Sciences by 67.5% in the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after buying an additional 11,800 shares in the last quarter. Zacks Investment Management purchased a new position in shares of Exact Sciences in the third quarter worth about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Exact Sciences by 59.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after buying an additional 125,192 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.